Form 4: Tarsus Pharmaceuticals Executive Dianne C. Whitfield Reports Stock Transactions

Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On March 15, 2024, Dianne C. Whitfield, Chief Human Resources Officer of Tarsus Pharmaceuticals, had restricted stock units (RSUs) vest, resulting in the issuance of 11,711 shares of common stock.
• Following the vesting, Whitfield sold 4,314 shares on March 18, 2024, at a price of $30.60 per share to cover tax withholding obligations.
• After these transactions, Whitfield directly owns 34,181 shares of Tarsus Pharmaceuticals common stock and 30,670 restricted stock units.
• The RSUs were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan and vest in installments over several years, contingent upon continued service.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock transactions by an officer. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by an officer could be perceived neutrally or slightly negatively by shareholders, depending on the context and the overall market sentiment.

Key Dates